HDAC9 and breast cancer: Zeng et al. discovered that the mRNA level alteration of cytokine pathways caused by HDAC led to the downstream response via the LIFR-JAK1-STAT3 signaling-centered feedback loop, which restrained the efficacy of HDAC inhibitors in breast cancer [56].